ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.

Pravin T P Kaumaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.